The United Food and Commercial Workers Local 1500 Welfare Fund has filed an antitrust lawsuit against Johnson and Johnson in Pennsylvania’s Eastern District Court. The suit takes aim at the drug maker over its blockbuster innovator infliximab, Remicade.
The United Food and Commercial Workers Local 1500 Welfare Fund has filed an antitrust lawsuit against Johnson & Johnson in Pennsylvania’s Eastern District Court. The suit takes aim at the drug maker over its blockbuster innovator infliximab, Remicade.
The Pharma Letter reports that the union’s benefits fund has alleged anti-competitive behavior on Johnson & Johnson’s part. The complaint claims that the drug manufacturer has engaged in exclusionary contracting that is designed to maintain a monopoly on the US infliximab marketplace. The union, which represents grocery workers in the state of New York, seeks a jury trial over the drug maker’s contracting, rebate policies, and product bundling that it alleges are designed to block insurers from reimbursing for either of the 2 available biosimilar infliximab products, Inflectra and Renflexis.
The union is the second entity to challenge the reference drug sponsor in recent days; in September, Pfizer, maker of Inflectra, filed a district court lawsuit against Johnson & Johnson in the Eastern District of Pennsylvania. Pfizer alleged that Johnson & Johnson has effectively denied patients access to biosimilar therapies by threatening to withhold rebates from insurers unless they agree to exclude biosimilars from their formularies. The suit claims that as many as 70% of patients who have commercial insurance coverage are unable to gain access to Inflectra due to the drug maker’s conduct.
Johnson & Johnson said in a statement concerning the Pfizer case that “Competition is doing what competition is meant to do: driving deeper discounts that will lead to overall lower costs for infliximab, including [Remicade]. We stand by our contracts.” The reference infliximab sponsor added that “Rather than demonstrating value and working to win the trust of physicians and patients, Pfizer is asking the court to protect it from having to compete.”
Additionally, the company highlighted the fact biosimilars are not generics, and not identical to reference products. It suggested that, instead, Pfizer’s Inflectra is a new medicine that has not yet proven itself before physicians, payers, or patients.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.